Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA

Key Points

• Bank of New York Mellon purchased 697,971 shares of Taysha Gene Therapies worth approximately $4.75 million, giving it a 0.24% stake. Institutional investors collectively own 77.7% of the company.
• Taysha shares opened at $5.60, with a 12-month range of $2.71 to $7.30 and a market capitalization of about $1.82 billion. The company’s latest quarterly loss of $0.13 per share missed analyst expectations by $0.02.
• Analysts maintain a generally positive view, with an average rating of “Buy” and an average price target of $12.77. However, an insider recently sold 200,000 shares for $1.25 million under a pre-arranged trading plan.

Bank of New York Mellon Corp purchased a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 697,971 shares of the company's stock, valued at approximately $4,753,000. Bank of New York Mellon Corp owned 0.24% of Taysha Gene Therapies at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. AQR Capital Management LLC increased its stake in shares of Taysha Gene Therapies by 325.6% in the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company's stock worth $150,000 after purchasing an additional 82,545 shares in the last quarter. Rhumbline Advisers grew its holdings in Taysha Gene Therapies by 13.5% during the second quarter. Rhumbline Advisers now owns 233,256 shares of the company's stock valued at $539,000 after purchasing an additional 27,794 shares during the period. Prudential Financial Inc. grew its holdings in Taysha Gene Therapies by 50.5% during the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company's stock valued at $53,000 after purchasing an additional 7,650 shares during the period. Invesco Ltd. increased its position in Taysha Gene Therapies by 27.4% in the second quarter. Invesco Ltd. now owns 203,671 shares of the company's stock worth $470,000 after buying an additional 43,772 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Taysha Gene Therapies in the second quarter worth about $184,000. Hedge funds and other institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Stock Up 0.5%

NASDAQ TSHA opened at $5.60 on Friday. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. Taysha Gene Therapies, Inc. has a 12 month low of $2.71 and a 12 month high of $7.30. The stock's 50 day moving average is $6.06 and its 200 day moving average is $5.63. The stock has a market cap of $1.82 billion, a PE ratio of -13.33 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Research analysts predict that Taysha Gene Therapies, Inc. will post -0.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TSHA has been the topic of a number of analyst reports. Pivotal Research set a $14.00 price objective on Taysha Gene Therapies in a research report on Tuesday, June 23rd. Wall Street Zen lowered shares of Taysha Gene Therapies from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Citizens Jmp restated a "market outperform" rating and set a $11.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, July 2nd. BMO Capital Markets lifted their price target on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the company an "outperform" rating in a report on Tuesday, June 23rd. Finally, The Goldman Sachs Group upped their price target on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $12.77.

Insider Activity

In related news, insider Sukumar Nagendran sold 200,000 shares of the business's stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the sale, the insider directly owned 936,410 shares in the company, valued at approximately $5,843,198.40. The trade was a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company's stock.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.